Ampersand Capital Partners-backed StageBio to merge with Alizée Pathology.

Ampersand Capital Partners-backed StageBio, a provider of GLP-compliant research and preclinical histology, pathology and specimen archiving services, agreed to merge with Alizée Pathology, a preclinical medical device laboratory in North America. Financial terms were not disclosed. "Dr. Serge Rousselle, Dr. Joan Wicks and the Alizée staff bring unique histopathology capabilities to StageBio. These services enable us to offer the industry an even broader range of highly specialized histopathology and imaging services. We have successfully merged HSRL, VPS and TPS, and are excited to add Alizée's expertise to our growing list of offerings," Thomas Galati, StageBio CEO.